摘要
目的探讨DOS(多西他赛联合奥沙利铂、替吉奥)方案在进展期胃腺癌D2根治术后辅助化疗中的疗效。方法回顾性分析晋城市人民医院2017年1月至2019年1月130例进展期胃腺癌行D2根治术后辅助化疗患者的临床资料,依据治疗方案分为DOS方案化疗组(DOS组,63例)和SOX(奥沙利铂、替吉奥)方案化疗组(SOX组,67例)。比较两组患者近期疗效及不良反应。结果因治疗时间不规律原因两组中各脱组2例,最终DOS组61例,SOX组65例。DOS组1、2、3年无病生存(DFS)率分别为80.33%、73.77%、62.30%,SOX组分别为73.85%、55.38%、43.54%,两组间DFS差异有统计学意义(χ^(2)=5.43,P=0.022);DOS组1、2、3年总生存(OS)率分别为93.44%、80.33%、70.50%,SOX组分别为96.92%、73.85%、52.31%,两组间OS差异有统计学意义(χ^(2)=4.38,P=0.045)。两组间Ⅰ~Ⅱ级恶心呕吐、腹泻、骨髓抑制、乏力发生率差异均无统计学意义(均P>0.05);Ⅲ~Ⅳ级恶心呕吐、乏力发生率差异均无统计学意义(均P>0.05),而Ⅲ~Ⅳ级腹泻、骨髓抑制发生率差异均有统计学意义(均P<0.05)。结论 DOS方案辅助治疗进展期胃腺癌D2根治术后患者疗效好,可延长生存期,不良反应可耐受。
Objective To investigate the efficacy and safety of DOS regimen in adjuvant chemotherapy after D2 radical resection for advanced gastric adenocarcinoma.Methods The clinical data of 130 patients who received adjuvant chemotherapy after D2 radical resection for advanced gastric adenocarcinoma in Jincheng People's Hospital from January 2017 to January 2019 were retrospectively analyzed.According to treatment regimens,the patients were divided into DOS regimen chemotherapy group(DOS group,63 cases)and SOX(oxaliplatin,S-1)regimen chemotherapy group(SOX group,67 cases).The short-term efficacy and adverse reactions of the two groups were compared.Results Due to the irregular treatment time,2 cases in each group were removed.Finally,there were 61 cases in DOS group and 65 cases in SOX group.The 1-,2-and 3-year disease-free survival(DFS)rates of the DOS group were 80.33%,73.77%and 62.30%,and the DFS rates of the SOX group were 73.85%,55.38%and 41.54%.The difference in DFS between the two groups was statistically significant(χ^(2)=5.43,P=0.022).The 1-,2-and 3-year overall survival(OS)rates of the DOS group were 93.44%,80.33%and 70.50%,and the OS rates of the SOX group were 96.92%,73.85%and 52.31%.The difference in OS between the two groups was statistically significant(χ^(2)=4.38,P=0.045).There were no statistical differences in the incidence rates of gradeⅠ-Ⅱnausea,vomiting,diarrhea,bone marrow suppression and fatigue between the two groups(all P>0.05).There were no statistical differences in the incidence rates of gradeⅢ-Ⅳnausea,vomiting and fatigue(both P>0.05),but there were statistical significances in the incidence rates of gradeⅢ-Ⅳdiarrhea and bone marrow suppression(both P<0.05).Conclusions Adjuvant DOS regimen in the treatment of advanced gastric adenocarcinoma after D2 radical resection has good curative efficacy and can improve the survival of patients,and the adverse reactions can be tolerated.
作者
王雪
王纪青
刘松雷
李爱萍
马凯
Wang Xue;Wang Jiqing;Liu Songlei;Li Aiping;Ma Kai(Department of Oncology,Jincheng People's Hospital,Jincheng 048026,China)
出处
《肿瘤研究与临床》
CAS
2022年第7期525-528,共4页
Cancer Research and Clinic
基金
山西省卫生和计划生育委员会青年课题(201601068)。
关键词
胃肿瘤
药物疗法
联合
化学疗法
辅助
预后
Stomach neoplasms
Drug therapy,combination
Chemotherapy,adjuvant
Prognosis
